Cerus (NASDAQ:CERS) Sets New 12-Month Low After Insider Selling

Share on StockTwits

Cerus Co. (NASDAQ:CERS) reached a new 52-week low during trading on Monday following insider selling activity. The stock traded as low as $3.95 and last traded at $3.95, with a volume of 30983 shares. The stock had previously closed at $4.09.

Specifically, Director Gail Schulze sold 15,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $4.19, for a total transaction of $62,850.00. Following the completion of the transaction, the director now owns 40,986 shares in the company, valued at approximately $171,731.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Carol Moore sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $5.33, for a total value of $159,900.00. The disclosure for this sale can be found here. Insiders own 7.26% of the company’s stock.

A number of brokerages have issued reports on CERS. ValuEngine lowered Cerus from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Zacks Investment Research upgraded Cerus from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. BTIG Research upgraded Cerus from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Wednesday, November 13th. BidaskClub lowered Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. Finally, Stifel Nicolaus began coverage on Cerus in a research report on Tuesday, August 27th. They set a “buy” rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Cerus presently has an average rating of “Hold” and an average target price of $7.50.

The company has a current ratio of 2.77, a quick ratio of 2.31 and a debt-to-equity ratio of 0.95. The stock has a 50-day simple moving average of $4.29 and a 200-day simple moving average of $4.92. The company has a market cap of $543.04 million, a price-to-earnings ratio of -8.73 and a beta of 1.57.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). Cerus had a negative return on equity of 100.59% and a negative net margin of 100.38%. The firm had revenue of $18.00 million during the quarter, compared to the consensus estimate of $17.69 million. During the same period in the prior year, the firm posted ($0.11) EPS. The firm’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, research analysts expect that Cerus Co. will post -0.5 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its stake in shares of Cerus by 9.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 27,477 shares of the biotechnology company’s stock worth $142,000 after buying an additional 2,455 shares in the last quarter. Raymond James Trust N.A. raised its stake in shares of Cerus by 13.6% in the 3rd quarter. Raymond James Trust N.A. now owns 25,000 shares of the biotechnology company’s stock worth $129,000 after buying an additional 3,000 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Cerus by 8.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 54,200 shares of the biotechnology company’s stock worth $279,000 after buying an additional 4,250 shares in the last quarter. Aperio Group LLC bought a new stake in shares of Cerus in the 2nd quarter worth $27,000. Finally, Prudential Financial Inc. raised its stake in shares of Cerus by 20.7% in the 2nd quarter. Prudential Financial Inc. now owns 34,297 shares of the biotechnology company’s stock worth $193,000 after buying an additional 5,880 shares in the last quarter. 75.02% of the stock is currently owned by institutional investors.

Cerus Company Profile (NASDAQ:CERS)

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: Inverted Yield Curve

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Axis Capital Target of Unusually High Options Trading
Axis Capital Target of Unusually High Options Trading
International Game Technology Sees Unusually High Options Volume
International Game Technology Sees Unusually High Options Volume
Personal Assets Trust  Sets New 12-Month High on Insider Buying Activity
Personal Assets Trust Sets New 12-Month High on Insider Buying Activity
Pennon Group  Reaches New 1-Year High Following Analyst Upgrade
Pennon Group Reaches New 1-Year High Following Analyst Upgrade
SEGRO  Sets New 52-Week High on Analyst Upgrade
SEGRO Sets New 52-Week High on Analyst Upgrade
BAE Systems  Sets New 52-Week High Following Analyst Upgrade
BAE Systems Sets New 52-Week High Following Analyst Upgrade


© 2006-2020 Ticker Report